UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations.

Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

Block & Leviton is investigating whether Unicycive Therapeutics made false or misleading statements to investors or failed to disclose material information about the FDA review of its OLC New Drug Application.

On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter for the resubmitted OLC NDA, citing the same third-party manufacturing deficiencies that had been identified in a prior Complete Response Letter in June 2025.

The company also stated that it understood the FDA had not yet inspected the third-party manufacturing vendor as part of its review of the resubmitted application.

Following this news, Unicycive's stock price declined.

Anyone who purchased Unicycive Therapeutics, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment.

Investors should contact Block & Leviton to learn more via our case website , by email at shareholders@blockle...